ADV-TK Improves Outcome of Recurrent High-Grade Glioma
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
Malignant gliomas are the most common primary brain tumor in adults, but the prognosis for
patients with these tumors remains poor despite advances in diagnosis and standard therapies
such as surgery, radiation therapy, and chemotherapy. The advantages of ADV-TK gene therapy
highlight its efficacy and safety for glioma patients. This clinical trial was conducted to
assess the anti-tumor efficacy and safety of intraarterial cerebral infusion of
replication-deficient adenovirus mutant ADV-TK, in combination with systemic intravenous GCV
administration in patients with recurrent high-grade glioma.
Phase:
Phase 2
Details
Lead Sponsor:
Huazhong University of Science and Technology
Collaborators:
Beijing Chao Yang Hospital Beijing Friendship Hospital Beijing Tiantan Hospital